Peter R. Carroll, MD, MPH

Ken and Donna Derr-Chevron Distinguished Professorship in Prostate Cancer; Taube Family Distinguished Professorship in Urology, UCSF

Associate Director, Strategic Planning and Clinical Services; and Program Leader, Prostate Cancer Program, Helen Diller Family Comprehensive Cancer Center; Associate Dean, School of Medicine; Chair, Department of Urology, UCSF

Cancer Center Program Membership

Prostate Cancer

Research Summary

My main research interests include identifying clinical and pathologic determinants of prostate cancer recurrence, progression, and mortality; discovering novel biomarkers for prostate cancer diagnostics and prognostics; developing evidence-based guidelines for improved management of prostate cancer patients; and examining the impact of lifestyle on health-related quality of life and survivorship among men with prostate cancer. Since 1995, I have been PI of CaPSURE™, a national disease registry study of over 14,000 men with prostate cancer treated at 40+ sites. At UCSF, we have developed a novel program in clinical management of and research on active surveillance for men with low-burden prostate cancer. We are committed to reducing the burden of prostate cancer treatment (physical, psychological and monetary). In 2007, I and colleagues initiated the Prostate Cancer Active Surveillance Study (PASS), a large multi-institutional cohort of men on active surveillance, designed to examine quantitative metabolic, molecular, and physiologic imaging biomarkers and lifestyle factors as novel predictors of prostate cancer progression. We aim to better determine which patients may safely avoid radical treatment, while concurrently identifying men who may benefit from early treatment instead of active surveillance.

Research Funding

  • August 5, 1999 - May 31, 2023 - Cancer Center Support Grant , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: P30CA082103
  • September 30, 2008 - July 31, 2020 - UCSF KURe Career Development Program , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: K12DK083021
  • September 30, 2009 - August 31, 2012 - Effectiveness of Early Stage Prostate Cancer Treatment , Principal Investigator . Sponsor: NIH, Sponsor Award ID: RC1CA146596
  • September 30, 2006 - August 31, 2012 - Male Reproductive Health Research Career Development Program , Principal Investigator . Sponsor: NIH, Sponsor Award ID: K12HD053943

Education

University of California, Berkeley, BA, 1974, Zoology
Georgetown University School of Medicine, Washington, D.C., MD, 1979, Medicine
University of California, Berkeley, MPH, 2008

Honors & Awards

  • Other Experience and Professional Memberships
  • 2002-present
    American Urological Association, Prize Essay Committee (Chair)
  • 2002-2008
    American Urological Association, Update Series Advisory Committee (member)
  • 2001-present
    American Board of Urology, Trustee, President Elect (2006-2008)
  • 2001-present
    American College of Surgeons Commission on Cancer, AUA representative
  • 2000-present
    American Association of Genitourinary Surgeons, Site Committee
  • 2003-present
    American Association of Genitourinary Surgeons, Councilor
  • 2004-present
    ASCO Prostate Cancer Committee, Symposium Committee
  • 2004-present
    ASCO, Oncology Taskforce
  • 2005-present
    ASCO, Cancer Communications Committee, Roster of Cancer Experts
  • 2005-present
    American College of Radiology’s Appropriateness Criteria Expert Panel on Radiation Oncology-Prostate, AUA representative
  • 2006-present
    The Journal of Urology, Associate Editor
  • 2011 – present
    AUA Update, Editor
  • Honors:
  • 2001
    Ken and Donna Derr - Chevron Endowed Chair in Prostate Cancer
  • 2002
    Clinical Society of the American Association of Genitourinary Surgeons
  • 2004
    Ken and Donna Derr-Chevron Distinguished Professorship in Prostate Cancer
  • 2010
    AUA Eugene Fuller Triennial Prostate Award
  • 2010
    Society of Urologic Oncology Medal
  • 2014
    Barringer Medal, American Association of Genitourinary Surgeons

Selected Publications

  1. Nik-Ahd F, De Hoedt A, Butler C, Anger JT, Carroll PR, Cooperberg MR, Freedland SJ. Prostate Cancer in Transgender Women in the Veterans Affairs Health System, 2000-2022. JAMA. 2023 Apr 29.  View on PubMed
  2. Parker R, Bell A, Chang K, Greenberg S, Washington SL, Cowan JE, Carroll PR, Cooperberg MR. PSA density does not improve predictive accuracy of the UCSF-CAPRA score. Prostate. 2023 Apr 20.  View on PubMed
  3. Nik-Ahd F, Waller J, De Hoedt AM, Garcia MM, Figueiredo JC, Carroll PR, Cooperberg MR, Freedland SJ. Seeing the unseen: how can we best identify transgender women within the Veterans Affairs healthcare system's electronic medical record? J Sex Med. 2023 03 31; 20(4):559-567.  View on PubMed
  4. Han JH, Herlemann A, Washington SL, Lonergan PE, Carroll PR, Cooperberg MR, Jeong CW. Observation, Radiotherapy, or Radical Prostatectomy for Localized Prostate Cancer: Survival Analysis in the United States. World J Mens Health. 2023 Mar 15.  View on PubMed
  5. Shee K, Cowan JE, Balakrishnan A, Escobar D, Chang K, Washington SL, Nguyen HG, Shinohara K, Cooperberg MR, Carroll PR. Limited Relevance of the Very Low Risk Prostate Cancer Classification in the Modern Era: Results from a Large Institutional Active Surveillance Cohort. Eur Urol. 2023 Mar 02.  View on PubMed
  6. Sabbagh A, Washington SL, Tilki D, Hong JC, Feng J, Valdes G, Chen MH, Wu J, Huland H, Graefen M, Wiegel T, Böhmer D, Cowan JE, Cooperberg M, Feng FY, Roach M, Trock BJ, Partin AW, D'Amico AV, Carroll PR, Mohamad O. Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate Cancer. Eur Urol Oncol. 2023 Mar 01.  View on PubMed
  7. Tilki D, Chen MH, Wu J, Huland H, Graefen M, Mohamad O, Cowan JE, Feng FY, Carroll PR, D'Amico AV. Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death. J Clin Oncol. 2023 Mar 01; JCO2202489.  View on PubMed
  8. Szymaniak JA, Washington SL, Cowan JE, Cooperberg MR, Lonergan PE, Nguyen HG, Meng MV, Carroll PR. The natural history of a delayed detectable PSA after radical prostatectomy. Prostate Cancer Prostatic Dis. 2023 Feb 10.  View on PubMed
  9. Gibbons M, Simko JP, Carroll PR, Noworolski SM. Prostate cancer lesion detection, volume quantification and high-grade cancer differentiation using cancer risk maps derived from multiparametric MRI with histopathology as the reference standard. Magn Reson Imaging. 2023 06; 99:48-57.  View on PubMed
  10. Van Blarigan EL, Chan JM, Sanchez A, Zhang L, Winters-Stone K, Liu V, Macaire G, Panchal N, Graff RE, Tenggara I, Luke A, Simko JP, Cooperberg MR, Carroll PR, Kenfield SA. Protocol for a 4-arm randomized controlled trial testing remotely delivered exercise-only, diet-only, and exercise + diet interventions among men with prostate cancer treated with radical prostatectomy (Prostate 8-II). Contemp Clin Trials. 2023 02; 125:107079.  View on PubMed
  11. Smith SM, Stelmar J, Lee G, Carroll PR, Garcia MM. Use of Voice Recordings in the Consultation of Patients Seeking Genital Gender-Affirming Surgery: An Opportunity for Broader Application Throughout Surgery? J Surg Res (Houst). 2022; 5(4):618-625.  View on PubMed
  12. Hunter DJ, McLachlan AJ, Carroll PR, Wakefield TAN, Stosic R. Health Literacy and Appropriateness of Self-Care and Pain Management in Osteoarthritis: An Understanding of the Patient's Perspective. Arthritis Care Res (Hoboken). 2023 04; 75(4):848-859.  View on PubMed
  13. Guan A, Shim JK, Allen L, Kuo MC, Lau K, Loya Z, Brooks JD, Carroll PR, Cheng I, Chung BI, DeRouen MC, Frosch DL, Golden T, Leppert JT, Lichtensztajn DY, Lu Q, Oh DL, Sieh W, Wadhwa M, Gomez SL, Shariff-Marco S. Factors that influence treatment decisions: A qualitative study of racially and ethnically diverse patients with low- and very-low risk prostate cancer. Cancer Med. 2023 03; 12(5):6307-6317.  View on PubMed
  14. Schenk JM, Liu M, Neuhouser ML, Newcomb LF, Zheng Y, Zhu K, Brooks JD, Carroll PR, Dash A, Ellis WJ, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Wagner AA, Lin DW. Dietary Patterns and Risk of Gleason Grade Progression among Men on Active Surveillance for Prostate Cancer: Results from the Canary Prostate Active Surveillance Study. Nutr Cancer. 2023; 75(2):618-626.  View on PubMed
  15. Nik-Ahd F, Jarjour A, Figueiredo J, Anger JT, Garcia M, Carroll PR, Cooperberg MR, Vidal AC, Freedland SJ. Prostate-Specific Antigen Screening in Transgender Patients. Eur Urol. 2023 Jan; 83(1):48-54.  View on PubMed
  16. Smith LH, García-Albéniz X, Chan JM, Zhao S, Cowan JE, Broering JM, Cooperberg MR, Carroll PR, Hernán MA. Emulation of a target trial with sustained treatment strategies: an application to prostate cancer using both inverse probability weighting and the g-formula. Eur J Epidemiol. 2022 Oct 26.  View on PubMed
  17. Weng X, Zhong L, Xiang P, Li Y, Paciorek A, Dong L, Broering J, Carroll PR, Sanda M, Wilson L. Cost-effectiveness analysis of primary treatments for localised prostate cancer: A population-based Markov analysis using real-world evidence. Eur J Cancer Care (Engl). 2022 Nov; 31(6):e13740.  View on PubMed
  18. Carroll P. Gleason Grade 1 Prostate Cancer Volume at Biopsy Is Associated With Upgrading, but Not Adverse Pathology or Recurrence After Radical Prostatectomy: Results From a Large Institutional Cohort. Reply. J Urol. 2023 Jan; 209(1):73.  View on PubMed
  19. Shee K, Washington SL, Cowan JE, de la Calle CM, Baskin AS, Chappidi MR, Escobar D, Nguyen HG, Cooperberg MR, Carroll PR. Gleason Grade 1 Prostate Cancer Volume at Biopsy Is Associated With Upgrading but Not Adverse Pathology or Recurrence After Radical Prostatectomy: Results From a Large Institutional Cohort. J Urol. 2022 Sep 06; 101097JU0000000000002956.  View on PubMed
  20. Langlais CS, Graff RE, Van Blarigan EL, Kenfield SA, Neuhaus J, Tabung FK, Cowan JE, Broering JM, Carroll P, Chan JM. Postdiagnostic Inflammatory, Hyperinsulinemic, and Insulin-Resistant Diets and Lifestyles and the Risk of Prostate Cancer Progression and Mortality. Cancer Epidemiol Biomarkers Prev. 2022 09 02; 31(9):1760-1768.  View on PubMed

Go to UCSF Profiles, powered by CTSI